nodes	percent_of_prediction	percent_of_DWPC	metapath
Formoterol—CYP2A6—esophageal cancer	0.807	1	CbGaD
Formoterol—Pharyngeal disorder—Capecitabine—esophageal cancer	0.00687	0.0682	CcSEcCtD
Formoterol—Tonsillitis—Capecitabine—esophageal cancer	0.00285	0.0283	CcSEcCtD
Formoterol—CYP2C9—Capecitabine—esophageal cancer	0.00244	0.665	CbGbCtD
Formoterol—Dobutamine—CA2—esophageal cancer	0.00224	0.569	CrCbGaD
Formoterol—Lower respiratory tract infection—Capecitabine—esophageal cancer	0.00211	0.0209	CcSEcCtD
Formoterol—Chronic obstructive pulmonary disease—Methotrexate—esophageal cancer	0.00188	0.0186	CcSEcCtD
Formoterol—Tooth abscess—Capecitabine—esophageal cancer	0.00172	0.0171	CcSEcCtD
Formoterol—Arformoterol—CYP2A6—esophageal cancer	0.0017	0.43	CrCbGaD
Formoterol—Paraesthesia oral—Capecitabine—esophageal cancer	0.00154	0.0152	CcSEcCtD
Formoterol—Abscess—Cisplatin—esophageal cancer	0.00123	0.0123	CcSEcCtD
Formoterol—CYP2C9—Cisplatin—esophageal cancer	0.00123	0.335	CbGbCtD
Formoterol—Infection—Carboplatin—esophageal cancer	0.00118	0.0117	CcSEcCtD
Formoterol—Oral candidiasis—Capecitabine—esophageal cancer	0.00113	0.0113	CcSEcCtD
Formoterol—Neck stiffness—Methotrexate—esophageal cancer	0.00113	0.0112	CcSEcCtD
Formoterol—Supraventricular tachycardia—Capecitabine—esophageal cancer	0.0011	0.0109	CcSEcCtD
Formoterol—Nuchal rigidity—Methotrexate—esophageal cancer	0.00103	0.0103	CcSEcCtD
Formoterol—Pain—Carboplatin—esophageal cancer	0.00102	0.0101	CcSEcCtD
Formoterol—Hyperkalaemia—Cisplatin—esophageal cancer	0.00096	0.00953	CcSEcCtD
Formoterol—Herpes zoster—Capecitabine—esophageal cancer	0.000956	0.0095	CcSEcCtD
Formoterol—Body temperature increased—Carboplatin—esophageal cancer	0.000939	0.00933	CcSEcCtD
Formoterol—Injection site pain—Capecitabine—esophageal cancer	0.000882	0.00876	CcSEcCtD
Formoterol—Dysphonia—Capecitabine—esophageal cancer	0.000875	0.00869	CcSEcCtD
Formoterol—Extrasystoles—Capecitabine—esophageal cancer	0.000856	0.0085	CcSEcCtD
Formoterol—Musculoskeletal stiffness—Capecitabine—esophageal cancer	0.000803	0.00797	CcSEcCtD
Formoterol—Skin discolouration—Capecitabine—esophageal cancer	0.000797	0.00792	CcSEcCtD
Formoterol—Ventricular extrasystoles—Capecitabine—esophageal cancer	0.000797	0.00792	CcSEcCtD
Formoterol—Rectal haemorrhage—Capecitabine—esophageal cancer	0.000797	0.00792	CcSEcCtD
Formoterol—Cardiac failure congestive—Cisplatin—esophageal cancer	0.000782	0.00776	CcSEcCtD
Formoterol—Herpes simplex—Capecitabine—esophageal cancer	0.000781	0.00776	CcSEcCtD
Formoterol—Nasal congestion—Cisplatin—esophageal cancer	0.000778	0.00773	CcSEcCtD
Formoterol—Nocturia—Capecitabine—esophageal cancer	0.000776	0.00771	CcSEcCtD
Formoterol—Paralysis—Methotrexate—esophageal cancer	0.000772	0.00766	CcSEcCtD
Formoterol—Lung disorder—Methotrexate—esophageal cancer	0.000757	0.00752	CcSEcCtD
Formoterol—Inflammation—Capecitabine—esophageal cancer	0.000742	0.00737	CcSEcCtD
Formoterol—Blood pressure increased—Capecitabine—esophageal cancer	0.00072	0.00715	CcSEcCtD
Formoterol—Herpes zoster—Methotrexate—esophageal cancer	0.000712	0.00707	CcSEcCtD
Formoterol—Melaena—Capecitabine—esophageal cancer	0.000703	0.00698	CcSEcCtD
Formoterol—Candida infection—Capecitabine—esophageal cancer	0.000688	0.00683	CcSEcCtD
Formoterol—Abscess—Methotrexate—esophageal cancer	0.000678	0.00673	CcSEcCtD
Formoterol—Dehydration—Cisplatin—esophageal cancer	0.00066	0.00655	CcSEcCtD
Formoterol—Neoplasm—Capecitabine—esophageal cancer	0.000651	0.00646	CcSEcCtD
Formoterol—Hypokalaemia—Cisplatin—esophageal cancer	0.000645	0.00641	CcSEcCtD
Formoterol—Cramp muscle—Cisplatin—esophageal cancer	0.000639	0.00634	CcSEcCtD
Formoterol—Nasopharyngitis—Cisplatin—esophageal cancer	0.000634	0.0063	CcSEcCtD
Formoterol—Abnormal vision—Capecitabine—esophageal cancer	0.000628	0.00624	CcSEcCtD
Formoterol—Sleep disorder—Capecitabine—esophageal cancer	0.000604	0.006	CcSEcCtD
Formoterol—Musculoskeletal stiffness—Methotrexate—esophageal cancer	0.000598	0.00593	CcSEcCtD
Formoterol—Skin discolouration—Methotrexate—esophageal cancer	0.000594	0.00589	CcSEcCtD
Formoterol—Bone disorder—Methotrexate—esophageal cancer	0.000594	0.00589	CcSEcCtD
Formoterol—Gastroenteritis—Capecitabine—esophageal cancer	0.00059	0.00586	CcSEcCtD
Formoterol—Herpes simplex—Methotrexate—esophageal cancer	0.000582	0.00578	CcSEcCtD
Formoterol—Inflammation—Methotrexate—esophageal cancer	0.000553	0.00549	CcSEcCtD
Formoterol—Atrial fibrillation—Capecitabine—esophageal cancer	0.000552	0.00548	CcSEcCtD
Formoterol—Acute coronary syndrome—Cisplatin—esophageal cancer	0.000539	0.00535	CcSEcCtD
Formoterol—Arthritis—Capecitabine—esophageal cancer	0.000538	0.00534	CcSEcCtD
Formoterol—Myocardial infarction—Cisplatin—esophageal cancer	0.000536	0.00532	CcSEcCtD
Formoterol—Conjunctivitis—Cisplatin—esophageal cancer	0.000531	0.00527	CcSEcCtD
Formoterol—Melaena—Methotrexate—esophageal cancer	0.000524	0.0052	CcSEcCtD
Formoterol—Cystitis noninfective—Methotrexate—esophageal cancer	0.000524	0.0052	CcSEcCtD
Formoterol—Cystitis—Methotrexate—esophageal cancer	0.000518	0.00514	CcSEcCtD
Formoterol—Dehydration—Capecitabine—esophageal cancer	0.000486	0.00483	CcSEcCtD
Formoterol—Bladder pain—Methotrexate—esophageal cancer	0.000485	0.00481	CcSEcCtD
Formoterol—Neoplasm—Methotrexate—esophageal cancer	0.000485	0.00481	CcSEcCtD
Formoterol—Urinary tract disorder—Cisplatin—esophageal cancer	0.000484	0.00481	CcSEcCtD
Formoterol—Connective tissue disorder—Cisplatin—esophageal cancer	0.000482	0.00479	CcSEcCtD
Formoterol—Urethral disorder—Cisplatin—esophageal cancer	0.000481	0.00477	CcSEcCtD
Formoterol—Dry skin—Capecitabine—esophageal cancer	0.000479	0.00476	CcSEcCtD
Formoterol—Hypokalaemia—Capecitabine—esophageal cancer	0.000476	0.00472	CcSEcCtD
Formoterol—Visual impairment—Cisplatin—esophageal cancer	0.000473	0.00469	CcSEcCtD
Formoterol—Nasopharyngitis—Capecitabine—esophageal cancer	0.000467	0.00464	CcSEcCtD
Formoterol—Gastritis—Capecitabine—esophageal cancer	0.000463	0.00459	CcSEcCtD
Formoterol—Cardiac disorder—Cisplatin—esophageal cancer	0.000455	0.00452	CcSEcCtD
Formoterol—Influenza—Capecitabine—esophageal cancer	0.000452	0.00449	CcSEcCtD
Formoterol—Asthma—Capecitabine—esophageal cancer	0.000452	0.00449	CcSEcCtD
Formoterol—Bronchospasm—Capecitabine—esophageal cancer	0.000444	0.00441	CcSEcCtD
Formoterol—Immune system disorder—Cisplatin—esophageal cancer	0.000443	0.0044	CcSEcCtD
Formoterol—Mediastinal disorder—Cisplatin—esophageal cancer	0.000442	0.00439	CcSEcCtD
Formoterol—Angina pectoris—Capecitabine—esophageal cancer	0.00044	0.00437	CcSEcCtD
Formoterol—Arrhythmia—Cisplatin—esophageal cancer	0.000438	0.00435	CcSEcCtD
Formoterol—Bronchitis—Capecitabine—esophageal cancer	0.000435	0.00431	CcSEcCtD
Formoterol—Malnutrition—Cisplatin—esophageal cancer	0.000427	0.00424	CcSEcCtD
Formoterol—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.00042	0.00417	CcSEcCtD
Formoterol—Muscle spasms—Cisplatin—esophageal cancer	0.000411	0.00408	CcSEcCtD
Formoterol—Hyperglycaemia—Capecitabine—esophageal cancer	0.000408	0.00405	CcSEcCtD
Formoterol—Tremor—Cisplatin—esophageal cancer	0.0004	0.00397	CcSEcCtD
Formoterol—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000397	0.00394	CcSEcCtD
Formoterol—Ill-defined disorder—Cisplatin—esophageal cancer	0.000396	0.00393	CcSEcCtD
Formoterol—Myocardial infarction—Capecitabine—esophageal cancer	0.000395	0.00392	CcSEcCtD
Formoterol—Urinary tract infection—Capecitabine—esophageal cancer	0.000392	0.00389	CcSEcCtD
Formoterol—Conjunctivitis—Capecitabine—esophageal cancer	0.000392	0.00389	CcSEcCtD
Formoterol—Malaise—Cisplatin—esophageal cancer	0.000385	0.00382	CcSEcCtD
Formoterol—Haematuria—Capecitabine—esophageal cancer	0.000384	0.00381	CcSEcCtD
Formoterol—Myalgia—Cisplatin—esophageal cancer	0.000364	0.00361	CcSEcCtD
Formoterol—Rhinitis—Capecitabine—esophageal cancer	0.000363	0.0036	CcSEcCtD
Formoterol—Anxiety—Cisplatin—esophageal cancer	0.000362	0.0036	CcSEcCtD
Formoterol—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000361	0.00359	CcSEcCtD
Formoterol—Discomfort—Cisplatin—esophageal cancer	0.000359	0.00357	CcSEcCtD
Formoterol—Pharyngitis—Capecitabine—esophageal cancer	0.000359	0.00356	CcSEcCtD
Formoterol—Urinary tract disorder—Capecitabine—esophageal cancer	0.000357	0.00355	CcSEcCtD
Formoterol—Oedema peripheral—Capecitabine—esophageal cancer	0.000356	0.00354	CcSEcCtD
Formoterol—Connective tissue disorder—Capecitabine—esophageal cancer	0.000355	0.00353	CcSEcCtD
Formoterol—Urethral disorder—Capecitabine—esophageal cancer	0.000355	0.00352	CcSEcCtD
Formoterol—Anaphylactic shock—Cisplatin—esophageal cancer	0.000349	0.00346	CcSEcCtD
Formoterol—Oedema—Cisplatin—esophageal cancer	0.000349	0.00346	CcSEcCtD
Formoterol—Visual impairment—Capecitabine—esophageal cancer	0.000349	0.00346	CcSEcCtD
Formoterol—Infection—Cisplatin—esophageal cancer	0.000346	0.00344	CcSEcCtD
Formoterol—Nervous system disorder—Cisplatin—esophageal cancer	0.000342	0.00339	CcSEcCtD
Formoterol—Tachycardia—Cisplatin—esophageal cancer	0.00034	0.00338	CcSEcCtD
Formoterol—Skin disorder—Cisplatin—esophageal cancer	0.000339	0.00336	CcSEcCtD
Formoterol—Asthma—Methotrexate—esophageal cancer	0.000336	0.00334	CcSEcCtD
Formoterol—Cardiac disorder—Capecitabine—esophageal cancer	0.000336	0.00333	CcSEcCtD
Formoterol—Immune system disorder—Capecitabine—esophageal cancer	0.000327	0.00324	CcSEcCtD
Formoterol—Mediastinal disorder—Capecitabine—esophageal cancer	0.000326	0.00324	CcSEcCtD
Formoterol—Hypotension—Cisplatin—esophageal cancer	0.000326	0.00323	CcSEcCtD
Formoterol—Arrhythmia—Capecitabine—esophageal cancer	0.000323	0.00321	CcSEcCtD
Formoterol—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000318	0.00315	CcSEcCtD
Formoterol—Mental disorder—Capecitabine—esophageal cancer	0.000317	0.00315	CcSEcCtD
Formoterol—Malnutrition—Capecitabine—esophageal cancer	0.000315	0.00313	CcSEcCtD
Formoterol—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000313	0.0031	CcSEcCtD
Formoterol—Dyspnoea—Cisplatin—esophageal cancer	0.000311	0.00309	CcSEcCtD
Formoterol—Dysgeusia—Capecitabine—esophageal cancer	0.000308	0.00306	CcSEcCtD
Formoterol—Back pain—Capecitabine—esophageal cancer	0.000305	0.00302	CcSEcCtD
Formoterol—Muscle spasms—Capecitabine—esophageal cancer	0.000303	0.00301	CcSEcCtD
Formoterol—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000301	0.00299	CcSEcCtD
Formoterol—Pain—Cisplatin—esophageal cancer	0.000298	0.00296	CcSEcCtD
Formoterol—Tremor—Capecitabine—esophageal cancer	0.000295	0.00293	CcSEcCtD
Formoterol—Ill-defined disorder—Capecitabine—esophageal cancer	0.000292	0.0029	CcSEcCtD
Formoterol—Conjunctivitis—Methotrexate—esophageal cancer	0.000292	0.00289	CcSEcCtD
Formoterol—Feeling abnormal—Cisplatin—esophageal cancer	0.000287	0.00285	CcSEcCtD
Formoterol—Haematuria—Methotrexate—esophageal cancer	0.000286	0.00284	CcSEcCtD
Formoterol—Malaise—Capecitabine—esophageal cancer	0.000284	0.00282	CcSEcCtD
Formoterol—Palpitations—Capecitabine—esophageal cancer	0.000278	0.00276	CcSEcCtD
Formoterol—Body temperature increased—Cisplatin—esophageal cancer	0.000276	0.00274	CcSEcCtD
Formoterol—Cough—Capecitabine—esophageal cancer	0.000275	0.00273	CcSEcCtD
Formoterol—Hypertension—Capecitabine—esophageal cancer	0.000272	0.0027	CcSEcCtD
Formoterol—Chest pain—Capecitabine—esophageal cancer	0.000268	0.00266	CcSEcCtD
Formoterol—Myalgia—Capecitabine—esophageal cancer	0.000268	0.00266	CcSEcCtD
Formoterol—Arthralgia—Capecitabine—esophageal cancer	0.000268	0.00266	CcSEcCtD
Formoterol—Pharyngitis—Methotrexate—esophageal cancer	0.000267	0.00265	CcSEcCtD
Formoterol—Anxiety—Capecitabine—esophageal cancer	0.000267	0.00265	CcSEcCtD
Formoterol—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000266	0.00264	CcSEcCtD
Formoterol—Urinary tract disorder—Methotrexate—esophageal cancer	0.000266	0.00264	CcSEcCtD
Formoterol—Discomfort—Capecitabine—esophageal cancer	0.000265	0.00263	CcSEcCtD
Formoterol—Urethral disorder—Methotrexate—esophageal cancer	0.000264	0.00262	CcSEcCtD
Formoterol—Dry mouth—Capecitabine—esophageal cancer	0.000262	0.0026	CcSEcCtD
Formoterol—Visual impairment—Methotrexate—esophageal cancer	0.000259	0.00258	CcSEcCtD
Formoterol—Oedema—Capecitabine—esophageal cancer	0.000257	0.00255	CcSEcCtD
Formoterol—Hypersensitivity—Cisplatin—esophageal cancer	0.000257	0.00255	CcSEcCtD
Formoterol—Infection—Capecitabine—esophageal cancer	0.000255	0.00253	CcSEcCtD
Formoterol—Nervous system disorder—Capecitabine—esophageal cancer	0.000252	0.0025	CcSEcCtD
Formoterol—Tachycardia—Capecitabine—esophageal cancer	0.000251	0.00249	CcSEcCtD
Formoterol—Asthenia—Cisplatin—esophageal cancer	0.00025	0.00248	CcSEcCtD
Formoterol—Cardiac disorder—Methotrexate—esophageal cancer	0.00025	0.00248	CcSEcCtD
Formoterol—Skin disorder—Capecitabine—esophageal cancer	0.00025	0.00248	CcSEcCtD
Formoterol—Immune system disorder—Methotrexate—esophageal cancer	0.000243	0.00241	CcSEcCtD
Formoterol—Mediastinal disorder—Methotrexate—esophageal cancer	0.000243	0.00241	CcSEcCtD
Formoterol—Hypotension—Capecitabine—esophageal cancer	0.00024	0.00238	CcSEcCtD
Formoterol—Diarrhoea—Cisplatin—esophageal cancer	0.000238	0.00237	CcSEcCtD
Formoterol—Mental disorder—Methotrexate—esophageal cancer	0.000236	0.00234	CcSEcCtD
Formoterol—Malnutrition—Methotrexate—esophageal cancer	0.000234	0.00233	CcSEcCtD
Formoterol—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000234	0.00232	CcSEcCtD
Formoterol—Insomnia—Capecitabine—esophageal cancer	0.000232	0.00231	CcSEcCtD
Formoterol—Dysgeusia—Methotrexate—esophageal cancer	0.000229	0.00228	CcSEcCtD
Formoterol—Dyspnoea—Capecitabine—esophageal cancer	0.000229	0.00227	CcSEcCtD
Formoterol—Back pain—Methotrexate—esophageal cancer	0.000227	0.00225	CcSEcCtD
Formoterol—Dyspepsia—Capecitabine—esophageal cancer	0.000226	0.00225	CcSEcCtD
Formoterol—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000222	0.0022	CcSEcCtD
Formoterol—Vomiting—Cisplatin—esophageal cancer	0.000222	0.0022	CcSEcCtD
Formoterol—Fatigue—Capecitabine—esophageal cancer	0.000222	0.0022	CcSEcCtD
Formoterol—Rash—Cisplatin—esophageal cancer	0.00022	0.00218	CcSEcCtD
Formoterol—Constipation—Capecitabine—esophageal cancer	0.00022	0.00218	CcSEcCtD
Formoterol—Pain—Capecitabine—esophageal cancer	0.00022	0.00218	CcSEcCtD
Formoterol—Dermatitis—Cisplatin—esophageal cancer	0.00022	0.00218	CcSEcCtD
Formoterol—Ill-defined disorder—Methotrexate—esophageal cancer	0.000217	0.00216	CcSEcCtD
Formoterol—Feeling abnormal—Capecitabine—esophageal cancer	0.000212	0.0021	CcSEcCtD
Formoterol—Malaise—Methotrexate—esophageal cancer	0.000211	0.0021	CcSEcCtD
Formoterol—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00021	0.00209	CcSEcCtD
Formoterol—Nausea—Cisplatin—esophageal cancer	0.000207	0.00206	CcSEcCtD
Formoterol—Cough—Methotrexate—esophageal cancer	0.000205	0.00203	CcSEcCtD
Formoterol—Urticaria—Capecitabine—esophageal cancer	0.000204	0.00203	CcSEcCtD
Formoterol—Abdominal pain—Capecitabine—esophageal cancer	0.000203	0.00202	CcSEcCtD
Formoterol—Body temperature increased—Capecitabine—esophageal cancer	0.000203	0.00202	CcSEcCtD
Formoterol—Arthralgia—Methotrexate—esophageal cancer	0.0002	0.00198	CcSEcCtD
Formoterol—Chest pain—Methotrexate—esophageal cancer	0.0002	0.00198	CcSEcCtD
Formoterol—Myalgia—Methotrexate—esophageal cancer	0.0002	0.00198	CcSEcCtD
Formoterol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000198	0.00197	CcSEcCtD
Formoterol—Discomfort—Methotrexate—esophageal cancer	0.000197	0.00196	CcSEcCtD
Formoterol—Anaphylactic shock—Methotrexate—esophageal cancer	0.000191	0.0019	CcSEcCtD
Formoterol—Infection—Methotrexate—esophageal cancer	0.00019	0.00189	CcSEcCtD
Formoterol—Hypersensitivity—Capecitabine—esophageal cancer	0.000189	0.00188	CcSEcCtD
Formoterol—Nervous system disorder—Methotrexate—esophageal cancer	0.000188	0.00186	CcSEcCtD
Formoterol—Skin disorder—Methotrexate—esophageal cancer	0.000186	0.00184	CcSEcCtD
Formoterol—Asthenia—Capecitabine—esophageal cancer	0.000184	0.00183	CcSEcCtD
Formoterol—Pruritus—Capecitabine—esophageal cancer	0.000182	0.0018	CcSEcCtD
Formoterol—Hypotension—Methotrexate—esophageal cancer	0.000179	0.00177	CcSEcCtD
Formoterol—Diarrhoea—Capecitabine—esophageal cancer	0.000176	0.00175	CcSEcCtD
Formoterol—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000174	0.00173	CcSEcCtD
Formoterol—Insomnia—Methotrexate—esophageal cancer	0.000173	0.00172	CcSEcCtD
Formoterol—Dyspnoea—Methotrexate—esophageal cancer	0.000171	0.00169	CcSEcCtD
Formoterol—Somnolence—Methotrexate—esophageal cancer	0.00017	0.00169	CcSEcCtD
Formoterol—Dizziness—Capecitabine—esophageal cancer	0.00017	0.00169	CcSEcCtD
Formoterol—Dyspepsia—Methotrexate—esophageal cancer	0.000168	0.00167	CcSEcCtD
Formoterol—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000165	0.00164	CcSEcCtD
Formoterol—Fatigue—Methotrexate—esophageal cancer	0.000165	0.00164	CcSEcCtD
Formoterol—Pain—Methotrexate—esophageal cancer	0.000164	0.00162	CcSEcCtD
Formoterol—Vomiting—Capecitabine—esophageal cancer	0.000163	0.00162	CcSEcCtD
Formoterol—Rash—Capecitabine—esophageal cancer	0.000162	0.00161	CcSEcCtD
Formoterol—Dermatitis—Capecitabine—esophageal cancer	0.000162	0.00161	CcSEcCtD
Formoterol—Headache—Capecitabine—esophageal cancer	0.000161	0.0016	CcSEcCtD
Formoterol—Feeling abnormal—Methotrexate—esophageal cancer	0.000158	0.00156	CcSEcCtD
Formoterol—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000156	0.00155	CcSEcCtD
Formoterol—Nausea—Capecitabine—esophageal cancer	0.000153	0.00152	CcSEcCtD
Formoterol—Urticaria—Methotrexate—esophageal cancer	0.000152	0.00151	CcSEcCtD
Formoterol—Body temperature increased—Methotrexate—esophageal cancer	0.000151	0.0015	CcSEcCtD
Formoterol—Abdominal pain—Methotrexate—esophageal cancer	0.000151	0.0015	CcSEcCtD
Formoterol—Hypersensitivity—Methotrexate—esophageal cancer	0.000141	0.0014	CcSEcCtD
Formoterol—Asthenia—Methotrexate—esophageal cancer	0.000137	0.00136	CcSEcCtD
Formoterol—Pruritus—Methotrexate—esophageal cancer	0.000135	0.00134	CcSEcCtD
Formoterol—Diarrhoea—Methotrexate—esophageal cancer	0.000131	0.0013	CcSEcCtD
Formoterol—Dizziness—Methotrexate—esophageal cancer	0.000126	0.00126	CcSEcCtD
Formoterol—Vomiting—Methotrexate—esophageal cancer	0.000122	0.00121	CcSEcCtD
Formoterol—Rash—Methotrexate—esophageal cancer	0.000121	0.0012	CcSEcCtD
Formoterol—Dermatitis—Methotrexate—esophageal cancer	0.00012	0.0012	CcSEcCtD
Formoterol—Headache—Methotrexate—esophageal cancer	0.00012	0.00119	CcSEcCtD
Formoterol—Nausea—Methotrexate—esophageal cancer	0.000114	0.00113	CcSEcCtD
Formoterol—ADRB2—Signaling by GPCR—AKAP13—esophageal cancer	6.71e-05	0.000797	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—GNG7—esophageal cancer	6.57e-05	0.000781	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—SLC10A2—esophageal cancer	6.57e-05	0.000781	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—CA1—esophageal cancer	6.57e-05	0.000781	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—GNG7—esophageal cancer	6.43e-05	0.000764	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—ADCYAP1—esophageal cancer	6.29e-05	0.000747	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—PDE4D—esophageal cancer	6.28e-05	0.000746	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—ADCYAP1—esophageal cancer	6.15e-05	0.000731	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—PDE4D—esophageal cancer	6.14e-05	0.000729	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	6.08e-05	0.000722	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—CA2—esophageal cancer	6.01e-05	0.000714	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—GNG7—esophageal cancer	5.97e-05	0.000709	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—GNG7—esophageal cancer	5.84e-05	0.000694	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—CXCL2—esophageal cancer	5.79e-05	0.000688	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—WWOX—esophageal cancer	5.75e-05	0.000683	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—CXCL2—esophageal cancer	5.67e-05	0.000673	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—WWOX—esophageal cancer	5.63e-05	0.000669	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—PLCE1—esophageal cancer	5.59e-05	0.000664	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—ADH7—esophageal cancer	5.59e-05	0.000664	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	5.54e-05	0.000658	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—FKBP1A—esophageal cancer	5.47e-05	0.00065	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—ANXA1—esophageal cancer	5.39e-05	0.00064	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—FKBP1A—esophageal cancer	5.35e-05	0.000636	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—WIF1—esophageal cancer	5.35e-05	0.000635	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	5.3e-05	0.00063	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—ANXA1—esophageal cancer	5.27e-05	0.000626	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—CXCL2—esophageal cancer	5.26e-05	0.000625	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—SST—esophageal cancer	5.24e-05	0.000622	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—WIF1—esophageal cancer	5.23e-05	0.000622	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—CXCL2—esophageal cancer	5.15e-05	0.000611	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—SST—esophageal cancer	5.12e-05	0.000609	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—GHRL—esophageal cancer	5.11e-05	0.000606	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—GHRL—esophageal cancer	4.99e-05	0.000593	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CSNK1A1—esophageal cancer	4.94e-05	0.000586	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—ADH1B—esophageal cancer	4.9e-05	0.000582	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—ANXA1—esophageal cancer	4.89e-05	0.000581	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	4.84e-05	0.000574	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CSNK1A1—esophageal cancer	4.83e-05	0.000574	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—ANXA1—esophageal cancer	4.78e-05	0.000568	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—SST—esophageal cancer	4.76e-05	0.000565	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—BLVRB—esophageal cancer	4.71e-05	0.00056	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—SLC52A3—esophageal cancer	4.71e-05	0.00056	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—TYMP—esophageal cancer	4.68e-05	0.000556	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—SST—esophageal cancer	4.65e-05	0.000553	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—GHRL—esophageal cancer	4.64e-05	0.000551	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—PFN1—esophageal cancer	4.62e-05	0.000548	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—CYP26A1—esophageal cancer	4.56e-05	0.000541	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—GHRL—esophageal cancer	4.54e-05	0.000539	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—PFN1—esophageal cancer	4.52e-05	0.000537	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—ALOX15—esophageal cancer	4.44e-05	0.000527	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—SLC52A3—esophageal cancer	4.34e-05	0.000515	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—BLVRB—esophageal cancer	4.34e-05	0.000515	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—SLC52A3—esophageal cancer	4.3e-05	0.00051	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—BLVRB—esophageal cancer	4.3e-05	0.00051	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—GSTO1—esophageal cancer	4.24e-05	0.000503	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—TPI1—esophageal cancer	4.24e-05	0.000503	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	4.21e-05	0.0005	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—ELMO1—esophageal cancer	4.15e-05	0.000493	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—ALDOB—esophageal cancer	4.06e-05	0.000482	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—ELMO1—esophageal cancer	4.06e-05	0.000482	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—AKAP13—esophageal cancer	4.05e-05	0.000482	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—SLC10A2—esophageal cancer	4.01e-05	0.000476	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—CA1—esophageal cancer	4.01e-05	0.000476	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—AKAP13—esophageal cancer	3.97e-05	0.000471	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—GAPDH—esophageal cancer	3.91e-05	0.000464	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—CRABP1—esophageal cancer	3.87e-05	0.00046	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	3.84e-05	0.000456	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—HIST1H2BM—esophageal cancer	3.74e-05	0.000444	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—PDE4D—esophageal cancer	3.71e-05	0.00044	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—SLC10A2—esophageal cancer	3.69e-05	0.000438	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—CA1—esophageal cancer	3.69e-05	0.000438	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—GNG7—esophageal cancer	3.68e-05	0.000438	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—CA2—esophageal cancer	3.67e-05	0.000435	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—HIST1H2BM—esophageal cancer	3.66e-05	0.000435	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—SLC10A2—esophageal cancer	3.65e-05	0.000434	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—CA1—esophageal cancer	3.65e-05	0.000434	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—PDE4D—esophageal cancer	3.63e-05	0.000431	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	3.58e-05	0.000425	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—GNG7—esophageal cancer	3.53e-05	0.000419	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—ALDH2—esophageal cancer	3.45e-05	0.00041	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—GNG7—esophageal cancer	3.45e-05	0.00041	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—ADH7—esophageal cancer	3.41e-05	0.000405	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—PLCE1—esophageal cancer	3.41e-05	0.000405	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—CA2—esophageal cancer	3.37e-05	0.0004	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	3.37e-05	0.0004	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—CA2—esophageal cancer	3.34e-05	0.000397	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—XIAP—esophageal cancer	3.31e-05	0.000393	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—GSTT1—esophageal cancer	3.28e-05	0.00039	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	3.27e-05	0.000388	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—XIAP—esophageal cancer	3.23e-05	0.000384	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—PLCE1—esophageal cancer	3.13e-05	0.000372	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—ADH7—esophageal cancer	3.13e-05	0.000372	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CTNNA1—esophageal cancer	3.13e-05	0.000371	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CXCL2—esophageal cancer	3.11e-05	0.000369	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—ADH7—esophageal cancer	3.11e-05	0.000369	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—PLCE1—esophageal cancer	3.11e-05	0.000369	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—PTGS1—esophageal cancer	3.08e-05	0.000366	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—ENO1—esophageal cancer	3.08e-05	0.000366	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	3.07e-05	0.000365	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CTNNA1—esophageal cancer	3.06e-05	0.000363	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CXCL2—esophageal cancer	3.04e-05	0.000361	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—PSME1—esophageal cancer	3.03e-05	0.00036	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—PSME2—esophageal cancer	3.03e-05	0.00036	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—ADH1B—esophageal cancer	2.99e-05	0.000355	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—PSME2—esophageal cancer	2.9e-05	0.000345	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—PSME1—esophageal cancer	2.9e-05	0.000345	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—ANXA1—esophageal cancer	2.89e-05	0.000343	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—TYMP—esophageal cancer	2.86e-05	0.000339	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—PSME2—esophageal cancer	2.84e-05	0.000337	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—PSME1—esophageal cancer	2.84e-05	0.000337	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—ANXA1—esophageal cancer	2.83e-05	0.000336	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—SST—esophageal cancer	2.81e-05	0.000334	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—CYP26A1—esophageal cancer	2.78e-05	0.00033	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—SST—esophageal cancer	2.75e-05	0.000326	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—ADH1B—esophageal cancer	2.75e-05	0.000326	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—NOTCH3—esophageal cancer	2.74e-05	0.000325	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—GHRL—esophageal cancer	2.74e-05	0.000325	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—ADH1B—esophageal cancer	2.72e-05	0.000324	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—ALOX15—esophageal cancer	2.71e-05	0.000322	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—FBXW7—esophageal cancer	2.69e-05	0.00032	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—NOTCH3—esophageal cancer	2.68e-05	0.000318	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—GHRL—esophageal cancer	2.68e-05	0.000318	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—FBXW7—esophageal cancer	2.64e-05	0.000313	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—TYMP—esophageal cancer	2.63e-05	0.000312	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—CYP1B1—esophageal cancer	2.62e-05	0.000311	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—TYMP—esophageal cancer	2.6e-05	0.000309	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—TPI1—esophageal cancer	2.58e-05	0.000307	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—GSTO1—esophageal cancer	2.58e-05	0.000307	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—CYP26A1—esophageal cancer	2.56e-05	0.000303	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—CYP26A1—esophageal cancer	2.53e-05	0.000301	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—ALOX15—esophageal cancer	2.49e-05	0.000296	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—ALDOB—esophageal cancer	2.48e-05	0.000294	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—ALOX15—esophageal cancer	2.47e-05	0.000293	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—CYP19A1—esophageal cancer	2.46e-05	0.000292	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—NOTCH2—esophageal cancer	2.46e-05	0.000292	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—NOTCH2—esophageal cancer	2.4e-05	0.000285	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—GAPDH—esophageal cancer	2.38e-05	0.000283	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—GSTO1—esophageal cancer	2.38e-05	0.000282	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—TPI1—esophageal cancer	2.38e-05	0.000282	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—CRABP1—esophageal cancer	2.36e-05	0.000281	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—GSTO1—esophageal cancer	2.35e-05	0.00028	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—TPI1—esophageal cancer	2.35e-05	0.00028	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—ALDOB—esophageal cancer	2.28e-05	0.00027	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—ALDOB—esophageal cancer	2.26e-05	0.000268	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—GNG7—esophageal cancer	2.25e-05	0.000267	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—HMOX1—esophageal cancer	2.25e-05	0.000267	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—GAPDH—esophageal cancer	2.19e-05	0.00026	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—TGFBR2—esophageal cancer	2.18e-05	0.000259	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—GAPDH—esophageal cancer	2.17e-05	0.000258	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—CRABP1—esophageal cancer	2.17e-05	0.000258	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—ABCB1—esophageal cancer	2.15e-05	0.000256	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—CRABP1—esophageal cancer	2.15e-05	0.000256	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—TGFBR2—esophageal cancer	2.13e-05	0.000253	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—ALDH2—esophageal cancer	2.11e-05	0.00025	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—GNG7—esophageal cancer	2.07e-05	0.000245	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—SMAD4—esophageal cancer	2.06e-05	0.000245	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—GNG7—esophageal cancer	2.05e-05	0.000243	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—SMAD4—esophageal cancer	2.02e-05	0.00024	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—GSTT1—esophageal cancer	2e-05	0.000238	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—CYP2A6—esophageal cancer	1.98e-05	0.000235	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.97e-05	0.000234	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—ALDH2—esophageal cancer	1.94e-05	0.00023	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—ALDH2—esophageal cancer	1.92e-05	0.000228	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—PTGS1—esophageal cancer	1.88e-05	0.000223	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—ENO1—esophageal cancer	1.88e-05	0.000223	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—PSME2—esophageal cancer	1.85e-05	0.00022	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—PSME1—esophageal cancer	1.85e-05	0.00022	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—GSTT1—esophageal cancer	1.84e-05	0.000219	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—GSTT1—esophageal cancer	1.83e-05	0.000217	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—CYP2A6—esophageal cancer	1.82e-05	0.000216	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—CYP2A6—esophageal cancer	1.8e-05	0.000214	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.8e-05	0.000214	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—ENO1—esophageal cancer	1.73e-05	0.000205	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—PTGS1—esophageal cancer	1.73e-05	0.000205	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—PTGS1—esophageal cancer	1.71e-05	0.000203	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—ENO1—esophageal cancer	1.71e-05	0.000203	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—PSME2—esophageal cancer	1.7e-05	0.000202	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—PSME1—esophageal cancer	1.7e-05	0.000202	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—HIF1A—esophageal cancer	1.69e-05	0.0002	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—PSME1—esophageal cancer	1.69e-05	0.0002	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—PSME2—esophageal cancer	1.69e-05	0.0002	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—HIF1A—esophageal cancer	1.65e-05	0.000196	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.61e-05	0.000192	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—KDR—esophageal cancer	1.61e-05	0.000192	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—CYP1B1—esophageal cancer	1.6e-05	0.000189	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—KDR—esophageal cancer	1.58e-05	0.000188	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—NOTCH1—esophageal cancer	1.52e-05	0.000181	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—CYP19A1—esophageal cancer	1.5e-05	0.000178	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—NOTCH1—esophageal cancer	1.49e-05	0.000177	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.47e-05	0.000175	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—CYP1B1—esophageal cancer	1.47e-05	0.000174	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—CYP1B1—esophageal cancer	1.45e-05	0.000173	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—CREBBP—esophageal cancer	1.44e-05	0.000171	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—CYP19A1—esophageal cancer	1.38e-05	0.000164	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CREBBP—esophageal cancer	1.38e-05	0.000164	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—HMOX1—esophageal cancer	1.37e-05	0.000163	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—CYP19A1—esophageal cancer	1.37e-05	0.000162	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—EGFR—esophageal cancer	1.35e-05	0.000161	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CREBBP—esophageal cancer	1.35e-05	0.00016	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.34e-05	0.000159	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—EGFR—esophageal cancer	1.33e-05	0.000157	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—ABCB1—esophageal cancer	1.31e-05	0.000156	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—PIK3CA—esophageal cancer	1.29e-05	0.000154	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—NOS3—esophageal cancer	1.29e-05	0.000153	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—PIK3CA—esophageal cancer	1.27e-05	0.00015	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—HMOX1—esophageal cancer	1.26e-05	0.00015	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—HMOX1—esophageal cancer	1.25e-05	0.000148	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—NOS3—esophageal cancer	1.23e-05	0.000147	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.22e-05	0.000145	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—ABCB1—esophageal cancer	1.21e-05	0.000144	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—NOS3—esophageal cancer	1.21e-05	0.000143	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—ABCB1—esophageal cancer	1.2e-05	0.000142	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—PTGS2—esophageal cancer	1.18e-05	0.00014	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—PIK3CA—esophageal cancer	1.18e-05	0.00014	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—ERBB2—esophageal cancer	1.15e-05	0.000137	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—PIK3CA—esophageal cancer	1.15e-05	0.000137	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—ERBB2—esophageal cancer	1.13e-05	0.000134	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CCND1—esophageal cancer	1.02e-05	0.000121	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CCND1—esophageal cancer	9.98e-06	0.000119	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	9.93e-06	0.000118	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CDKN1A—esophageal cancer	9.87e-06	0.000117	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—EP300—esophageal cancer	9.81e-06	0.000116	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CDKN1A—esophageal cancer	9.65e-06	0.000115	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—EP300—esophageal cancer	9.39e-06	0.000112	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—EP300—esophageal cancer	9.18e-06	0.000109	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	9.06e-06	0.000108	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—CREBBP—esophageal cancer	8.78e-06	0.000104	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—MYC—esophageal cancer	8.18e-06	9.72e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—CREBBP—esophageal cancer	8.08e-06	9.59e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—CREBBP—esophageal cancer	8.01e-06	9.51e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—MYC—esophageal cancer	8e-06	9.51e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—EGFR—esophageal cancer	8e-06	9.5e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—NOS3—esophageal cancer	7.86e-06	9.34e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—EGFR—esophageal cancer	7.83e-06	9.3e-05	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—PIK3CA—esophageal cancer	7.26e-06	8.62e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—NOS3—esophageal cancer	7.23e-06	8.59e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—PTGS2—esophageal cancer	7.19e-06	8.54e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—NOS3—esophageal cancer	7.17e-06	8.51e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—PIK3CA—esophageal cancer	6.95e-06	8.25e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—PIK3CA—esophageal cancer	6.79e-06	8.07e-05	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—TP53—esophageal cancer	6.72e-06	7.98e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—PTGS2—esophageal cancer	6.61e-06	7.85e-05	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—TP53—esophageal cancer	6.57e-06	7.81e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—PTGS2—esophageal cancer	6.56e-06	7.79e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—EP300—esophageal cancer	5.98e-06	7.1e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—EP300—esophageal cancer	5.5e-06	6.53e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—EP300—esophageal cancer	5.45e-06	6.48e-05	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—PIK3CA—esophageal cancer	4.42e-06	5.25e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—PIK3CA—esophageal cancer	4.07e-06	4.83e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—PIK3CA—esophageal cancer	4.03e-06	4.79e-05	CbGpPWpGaD
